Drugs and Breast Cancer-Related Lymphoedema (BCRL): Incidence and Progression

Purpose of Review What is the current evidence for the role of drugs as risk factors for the development of breast cancer-related lymphoedema (BCRL) and in exacerbating existing BCRL? What are the mechanisms by which these effects occur? Recent Findings There is now evidence that taking calcium channel blockers (CCBs) during and after breast cancer treatment and receiving docetaxel chemotherapy are risk factors for the development of BCRL. CCBs cause oedema by increasing capillary filtration and docetaxel by inhibiting lymphatic vessel contractions. Ideally, CCBs should be avoided during and after treatment for breast cancer, but alternative options include changing to CCBs with a lower risk of causing oedema. An awareness of the potential role of medications in increasing the risk of BCRL and exacerbating existing BCRL is important in the appropriate management of patients treated for breast cancer.